Actionable news
All posts from Actionable news
Actionable news in ACAD: ACADIA Pharmaceuticals Inc.,

Alzheimer's and AAMI Reviewed by NeuroPerspective

SAN DIEGO, Sept. 8, 2016 /PRNewswire/ -- NI Research has released the September/October issue of NeuroPerspective, which features a comprehensive review of Alzheimer's therapeutics. Alzheimer's constitutes the single largest opportunity in the pharma world, but it also presents a daunting legacy of clinical disappointments.

The neuroscience area had for some time allowed theory to drive the science, instead of the other way around, and as a result, the path to disease-modifying therapies has seen little headway made, and symptomatic treatments have taken on greater relative importance. There are programs that have shown hints of a therapeutic signal, but their magnitude has raised the question of whether statistical significance will translate into clinical significance.

As NeuroPerspective publisher Harry Tracy PhD notes: "The lack of options means that those in the real world treating Alzheimer's may gratefully add a new drug to the repertoire, so long as they are sure it is reasonably safe and they can say that it will probably help–even if the magnitude of that added benefit may be invisible to the naked eye. After all, everyone, including the companies, the patients, their families, and the prescribers, want to believe that their's is not an exercise in futility."

The September/October issue also includes a review of AAMI, Age-Associated Memory Impairment. In this context, AAMI refers not to a prodromal stage of pre-dementia, but to the diminution of memory...